Tympanogen

Tympanogen is a clinical-stage medical device company pioneering a shift from surgical to clinic-based procedures for eardrum repair. Its core technology, the Perf-Fix™ Otologic Gel Patch, is a minimally invasive treatment designed to replace traditional tympanoplasty surgery, aiming to reduce healthcare costs and improve patient access and outcomes. Founded in 2013/2014 by a team of engineers and physicians, the company is advancing Perf-Fix through clinical trials, supported by non-dilutive funding such as a recent $3.23 million NIH grant. Tympanogen's vision is to establish Perf-Fix as the new standard-of-care in outpatient ENT care.

Proprietary gel system for minimally invasive tissue repair, designed for clinic-based application to facilitate natural healing.

Competition primarily comes from the entrenched standard of surgical tympanoplasty. Other potential competitors include off-label use of existing materials (e.g., paper patches, gelatin sponges) which are often less effective, and other early-stage companies developing bioengineered grafts or adhesive technologies for minimally invasive repair.